Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
What is the optimal chemotherapy regimen for unresectable pancoast tumor: cisplatin and etoposide or weekly carboplatin/paclitaxel with radiation followed by durvalumab?
Related Questions
How do you decide between Neoadjuvant (Checkmate 816) and Peri-adjuvant (Keynote 671) chemoimmunotherapy for early stage NSCLC?
Has the MARS data for mesothelioma changed whether you would recommend surgery for these patients?
How would you approach a patient with limited stage SCLC who progressed immediately after completing chemoradiation with brain metastasis?
What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?
What is the preferred concurrent chemotherapy regimen for limited stage small cell lung cancer with severe reaction to etoposide?
What is your approach to obtain tissue diagnosis for a patient with a lung primary and spine metastasis?
Would you consider ALK-directed TKI for a ALK L1198F point mutation in a patient with metastatic lung adenocarcinoma after progressing through first line chemoimmunotherapy?
Would you offer a different ALK inhibitor to a patient receiving alectinib who had decompensation of liver function in the setting of preexisting cirrhosis?
How often, if ever, do patients with initially negative targetable mutation workup become positive later in recurrent lung cancer?
Would you add ALK-targeted therapy for patients with EGFR L858R-mutant lung adenocarcinoma who progress on targeted therapy and develop a concomitant STRN-ALK fusion?